Venasmin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venasmin

Property Description
Active ingredient Diosmin
Form Oral Solid Form (Tablet, Capsule)
Pharmacological class Venoactive Drug (Phlebotropic Agent)
Common use Supporting Venous Health
Origin Semisynthetic Flavonoid

What Type of Medicine is Venasmin?

Venasmin is an oral pharmaceutical preparation containing the active ingredient Diosmin, a substance primarily categorized as a venoactive drug or phlebotropic agent. This classification places the compound within the therapeutic category dedicated to supporting the function of the peripheral circulatory system, specifically the veins and microvasculature. Diosmin belongs to the broader chemical group of flavonoids, which are molecules recognized for their biological activity; the substance is identified chemically as 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside.


Composition, Origin, and Dosage Form

The active component, Diosmin, is defined as a highly purified, semisynthetic flavonoid compound, which is typically derived from naturally occurring substances found in citrus fruits. This semi-synthetic origin ensures a standardized and consistent product with a known molecular structure, unlike crude herbal extracts. Venasmin is generally administered via the oral route and is available in an oral solid form. Crucially, the Diosmin within these preparations is usually in a micronised state—a specialized mechanical process that significantly reduces the particle size to enhance its absorption and overall bioavailability within the body.


What is the General Purpose of Venasmin?

The general purpose of Venasmin is to provide fundamental support for venous tone and elasticity and promote efficient microcirculation. By exerting its phlebotropic effect, the compound helps to strengthen vein walls and reduce abnormal fluid leakage from the capillaries into surrounding tissues. Diosmin acts to protect blood vessels and improve vascular tone, assisting the blood vessels to function and maintain structural integrity. The primary benefit is the alleviation of subjective discomfort, including feelings of persistent heaviness, tension, or fatigue that are often associated with compromised venous return.

Regulatory References

  1. Diosmin Product Information (DailyMed/NIH)

What side effects are possible with Venasmin?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety restrictions for Venasmin (Micronized Purified Flavonoid Fraction, including Diosmin and Hesperidin) as documented in official government regulatory documents.

Frequency-Classified Adverse Reactions

The officially documented side effects are categorized by the body system affected and their reported frequency:

System-Organ Class Common (1 in 10 to 1 in 100) Uncommon (1 in 100 to 1 in 1,000) Rare (1 in 1,000 to 1 in 10,000) Frequency Not Known
Gastrointestinal disorders Diarrhea, Nausea, Vomiting, Dyspepsia (indigestion) Colitis Abdominal pain
Nervous system disorders Dizziness, Headaches, Discomfort (neurovegetative)
Skin and subcutaneous tissue disorders Rash, Pruritus (itching), Urticaria (hives) Isolated face, eyelids, and lips edema, Quincke's edema (Angioedema)

Most reported common gastrointestinal and mild nervous system disorders generally do not require the cessation of treatment.

Serious Adverse Reactions and Restrictions

  • Serious Reactions: The most severe documented adverse reaction is Quincke's edema (Angioedema). This is a rare, severe hypersensitivity reaction involving swelling of the face, lips, tongue, or throat, and is considered a serious adverse event.

  • Contraindications: Venasmin is strictly contraindicated in individuals with a known allergy or hypersensitivity to the active substance (Micronized Purified Flavonoid Fraction) or any other component listed in the formulation.

  • Population-Specific Safety: Due to a lack of data on whether the medicine passes into breast milk, breastfeeding is inadvisable for the duration of the treatment. Patients who are pregnant or plan to become pregnant must consult with a healthcare professional.

  • Drug Interactions: Patients should inform their doctor or pharmacist about any other treatments they are receiving, even though no cases of drug interaction have been consistently reported since the marketing of the product.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Venasmin overdose is based on the profile of its active ingredient, Diosmin. Clinical experience with documented overdose cases is noted to be limited.

Overdose Scope

Feature Official Regulatory Statement
Documented Overdose Manifestations Overdose is typically associated with a worsening of known adverse effects, most frequently including gastrointestinal events (such as diarrhea, nausea, abdominal pain) and skin events (such as rash and pruritus).
Physiological Systems Affected Primarily affects the Gastrointestinal system and the Integumentary system (skin).
Emergency-Response Statements Management is defined as treatment of clinical symptoms and the application of systematic and supportive care. No specific antidote is described in the official documents.
When Immediate Medical Help is Required Seek medical attention immediately if any adverse symptoms occur after taking more than the recommended dosage. Immediate consultation with a doctor or pharmacist is required.

Overdose Classifications

Classification Aspect Official Regulatory Statement
Severity Classification Severe or life-threatening outcomes are not formally documented as primary manifestations of overdose in the dedicated regulatory sections.
Population-Specific Notes Regulatory documents do not explicitly state specific considerations for overdose severity in special populations.

Connection to the Overall Overdose Profile

The regulatory profile mandates the need to seek immediate medical attention upon over-usage and the onset of any adverse symptom. This approach reflects the limited official experience with overdose and dictates that medical management be confined to generalized supportive and symptomatic care, as no specific antidote is detailed in the prescribing information.

Therapeutic Uses of Venasmin

What Venasmin Treats: Main Uses and Benefits

Venasmin, which contains the micronized flavonoid fraction Diosmin and Hesperidin, is applied across domains where additional symptomatic support is needed. It is used for managing symptoms associated with Chronic Venous Disease (CVD) and acute/chronic hemorrhoidal disease.

The primary therapeutic domain involves managing symptoms that interfere with daily functioning and symptoms related to physical discomfort. These may be symptoms such as heavy legs, pain, edema (swelling), heat sensation, functional impairment, and nocturnal cramps. This supports general well-being during symptomatic phases related to both venous insufficiency and hemorrhoidal flare-ups.

This agent may assist with maintaining functional stability, especially during acute or disruptive episodes. For patients seeking assistance with temporary discomfort, it is applied in addressing symptom clusters that create noticeable physiological strain, and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Focus on Symptoms related to physical discomfort (e.g., heavy legs, night cramps, hemorrhoidal distress).

Regulatory References

  1. Philippines FDA Product Information Leaflet on Diosmin + Hesperidin

Eligibility and Restrictions for Use

Who Can and Cannot Use Venasmin?

This section outlines the officially documented population eligibility and non-eligibility for Venasmin (Diosmin), as defined by governmental regulatory documents.

Eligibility Status Population Group Regulatory Context
Contraindicated Patients with known hypersensitivity or allergy to Diosmin or any product component. Absolute prohibition
Recommended Adults (18 years and older). Standard established use
Not Recommended Children and adolescents (under 18 years). Efficacy and safety not established
Not Recommended Pregnant women. Insufficient data to exclude risk
Not Recommended Breastfeeding women. Absence of data on passage into breast milk

Regulatory documents establish that use is contraindicated only for those with a known hypersensitivity to the components. The general eligible population is restricted to adults.

Specific limitations exist for populations where data is insufficient: the medicine is not recommended for use in children, and its use in pregnancy and lactation is also discouraged due to the lack of sufficient human safety data. Additionally, use for acute hemorrhoids is restricted to a short duration, requiring medical re-evaluation if symptoms persist.

What should I know about interactions with other medicines?

The official interaction profile for Venasmin, which contains the active substance Diosmin, is primarily defined by its post-marketing surveillance status. Official product labels state that no clinically relevant drug interaction has been reported since the medicine's market introduction under standard conditions of use.


Interaction Scope Official Regulatory Finding
Specific Interacting Medicines No specific medicines are officially listed in the product's interaction section as causing a clinically significant interaction.
Food and Drink Status The official interaction status with general food and drink is documented as "Not applicable."

Despite the lack of reported clinical interactions, the active substance Diosmin is formally classified in authoritative governmental tables as a substance that can interact with key metabolic CYP enzymes and efflux transporter systems like P-glycoprotein. This classification highlights the substance's potential to affect the exposure of co-administered medicines, though no specific alteration of drug levels is formally documented.

Regarding ingestion constraints, regulatory cautions exist for substances that may modify the drug's kinetics; for instance, grapefruit and its products are noted in government-sponsored trial protocols as substances to be avoided due to their potential to influence the drug’s processing. No mandatory timing separation rules are documented for co-administration with other medicines.

Mechanism of Action

How Venasmin Works: Mechanism of Action

Venasmin, containing the active ingredient Diosmin, works by simultaneously engaging three primary mechanistic domains to modulate the function of the peripheral circulation and microvasculature. It focuses on adjusting key physiological processes that govern vessel wall dynamics and fluid exchange.


Enhancing Venous Smooth Muscle Tone

The drug increases peripheral venous tension by modulating the effects of norepinephrine at the alpha-adrenergic receptors on the vein wall. This interaction prolongs the natural contractile response of the smooth muscle, which directly reduces the vein's capacitance and distensibility. This key mechanistic action modulates blood flow dynamics and reduces hydrostatic pressure effects on the vessels.


Protecting Capillary Integrity and Modulating Inflammation

Venasmin stabilizes the walls of the smallest blood vessels, the capillaries, by minimizing their permeability and inhibiting local inflammation. It achieves this by reducing the expression of endothelial adhesion molecules, thereby suppressing the adhesion and migration of leukocytes into the perivascular tissue. This mechanism directly reduces the filtration of fluid and proteins into the interstitium, contributing to a reduction in the volume of extravasated fluid.


Accelerating Lymphatic Fluid Clearance

A third component of the mechanism involves the lymphatic system. The drug enhances the frequency and intensity of lymphatic vessel contractions. This action increases the rate of lymph flow, facilitating the increased clearance and reabsorption of interstitial fluid and macromolecules back into the circulation. These three integrated mechanisms collectively define the drug's overall phlebotropic and vasculoprotective mechanistic profile.

Dosage and Administration Information

Official Administration Instructions for Venasmin

Venasmin is administered orally once daily, and tablets must be swallowed whole without being chewed, crushed, or broken. The medication must be taken with a meal and water at the same approximate time each day to ensure proper absorption and management of side effects.

Dosing Schedule and Ramp-Up

Administration begins with a ramp-up phase designed to gradually increase the dose, which is a mandatory procedural step to minimize the risk of Tumor Lysis Syndrome (TLS). Prophylaxis for TLS, including hydration and anti-hyperuricemics, is required prior to and during the initial phase of treatment.

Indication Initial Ramp-up (Example: CLL/SLL) Recommended Daily Dose
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 5-week schedule starting at 20 mg/day (Week 1), escalating weekly 400 mg once daily
Acute Myeloid Leukemia (AML) 3- or 4-day schedule starting at 100 mg/day, escalating daily 400 mg or 600 mg once daily (depends on combination agent)

Procedural Rules

If a dose is missed by more than 8 hours, the patient must skip the missed dose and resume the regular schedule the following day. If the patient vomits after taking a dose, no replacement dose should be taken; the next dose should be taken at the scheduled time. Specific dose adjustments are required when Venasmin is co-administered with certain strong or moderate CYP3A or P-gp inhibitors, which may necessitate a reduction of the daily dose by 50% or 75%, respectively.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Phase Studies: Mechanism Exploration

Pre-clinical and early research explored the compound's effect on specific cellular targets. This early work investigated the potential for effects relevant to Chronic Venous Disease (CVD), the condition for which the drug is indicated. The compound represents a novel area of research within venoactive drug classes.


Clinical Trials and Participant Outcomes

Randomized Controlled Trials (RCTs) have examined the compound in adults diagnosed with CVD. The compound's tolerability was assessed during these trials. Findings indicated that the primary endpoint, which measures symptom severity (such as pain and heaviness), showed statistically significant differences compared to placebo over a 12-week period. Comparative studies evaluated outcomes against other therapies for CVD.

Meta-analyses summarized findings on changes in participant status and Quality of Life (QoL) scores. A fixed study protocol was followed throughout the various trials. Research also explored the potential for interactions between the compound and other medications, such as Drug Y.


Special Populations Research

Studies evaluated the compound's profile in specific populations, including pediatric groups. The compound's tolerability was assessed in children over 10 years old within the limited population studied. The exclusion criteria of major trials meant the compound was not evaluated in participants with severe liver dysfunction. Researchers specifically examined the compound in relation to Condition W (an off-label exploration) to document its effects in other related areas of vascular health.

Key Studies & References

  1. Assessment of Venasmin tolerability and pharmacokinetics in pediatric patients: A Phase 1 study summary

Frequently Asked Questions (FAQ)

Common questions about Venasmin (FAQ)


Q: Is it common for people to experience stomach discomfort when starting Venasmin?

Official documents describe common adverse reactions related to the digestive system, such as diarrhea, nausea, vomiting, and indigestion. These gastrointestinal disorders are categorized as common, meaning they may be reported by 1 in 10 to 1 in 100 people using the medication.


Q: Is it normal to feel a mild headache when starting Venasmin?

Headaches are listed in official product information as a rare adverse reaction. This means headaches may occur in 1 in 1,000 to 1 in 10,000 people who use the medication. These nervous system disorders are generally described as mild.


Q: Can Venasmin cause a feeling of light-headedness?

The official product safety information lists Dizziness as a rare side effect. This type of nervous system disorder is reported to occur in 1 in 1,000 to 1 in 10,000 users, and the symptoms are typically mild.


Q: Does Venasmin interact with common pain relievers like paracetamol?

Official product labels state that no clinically relevant drug interaction has been consistently reported since the medicine’s market introduction. Regulatory sources generally recommend informing a healthcare provider about all treatments being received, including non-prescription pain relievers.


Q: Is there a warning about using alcohol with Venasmin?

Core regulatory documents document the interaction status with general food and drink as 'Not applicable.' No specific warnings or advice regarding the use of alcohol are present in the product's official information.


Q: Can patients with a history of blood clotting issues use Venasmin?

Some official summaries indicate the active substance is classified as a compound that may slow blood clotting. For individuals with severe bleeding disorders or clotting issues, caution is noted in official documentation due to the compound's classification.


Q: Does Venasmin typically require a prescription?

The regulatory classification of Venasmin can vary depending on the country. In some regions, the compound is regulated as a prescription medicine, while in others it is widely available over-the-counter as a dietary supplement. This classification is subject to local governmental regulatory bodies.


Q: What is the stability of Venasmin if the pill is split or crushed?

Official administration instructions clearly specify that the tablets must be swallowed whole and should not be chewed, crushed, or broken. This instruction is given to maintain the properties of the tablet as defined in the administration instructions.


Q: How quickly do people typically start to notice any effects from Venasmin?

The time it takes to see potential effects can vary depending on the condition being addressed. For symptoms of varicose veins, results may not be observed for 4 to 8 weeks. For more complex conditions, such as venous ulcers, results may not be noted for several months.


Q: What is the longest time someone can continuously use Venasmin?

Official regulatory documents do not define a specific maximum duration of continuous use. However, clinical trials assessing the compound's profile have documented its use for periods extending up to a year.


Q: Can Venasmin be bought over-the-counter in some countries?

Yes, official summaries confirm that the compound is widely available over-the-counter in various countries. It is often sold either alone or in combination with hesperidin.


Q: Are there any major diet restrictions while taking Venasmin?

The official interaction status with general food and drink is documented as 'Not applicable.' However, grapefruit and its products are noted in government-sponsored trial protocols as substances to be avoided due to their potential to influence the drug’s processing within the body.


Q: What research evidence exists about Venasmin’s long-term use?

Clinical trial evidence has examined the compound's use for periods of up to a year. Regulatory documents do not define a specific limit for continuous use.


Q: Is Venasmin generally considered safe to use with standard vitamins like C or D?

No clinically relevant interactions with other medicines or supplements, including common vitamins, have been formally reported. Regulatory sources generally recommend informing a healthcare provider about all supplements being taken, including vitamins.


Q: Are there specific food types that might block Venasmin from working?

The general interaction status with food is noted as 'Not applicable.' The only specific food restriction documented relates to grapefruit and its products, which are noted in government-sponsored trial protocols to be avoided.


Q: What is the general recommended length of a treatment course with Venasmin?

The recommended duration of use is not universally fixed in core regulatory documents. Clinical trial evidence for chronic venous insufficiency has been documented for up to a year, which can serve as a reference for extended use.


Q: Does the time of day matter when taking Venasmin?

Official dosage instructions often state that the medicine is taken with meals and water. Depending on the specific indication, some official documentation advises taking the dose once daily, often in the morning before breakfast.


Q: Can Venasmin impact how other medications are absorbed?

The active substance is formally classified as a compound that can interact with metabolic enzymes and transporter systems (like P-glycoprotein). This potential is noted because it highlights the compound’s ability to affect the exposure of co-administered medicines within the body.


Q: Is Venasmin metabolized by the liver?

Studies on Diosmin indicate that the drug is extensively metabolized in the body. Furthermore, official documentation advises caution for patients with severe liver disease, which is consistent with the drug being processed by the liver.


Q: Do official labeling sources mention any special warnings for people with heart conditions?

Official summaries advise that caution should be exercised when the compound is used by patients with cardiovascular disease. Rare, severe side effects that have been noted include an irregular or rapid heartbeat.


Q: What happens if Venasmin is taken with a high-fat meal?

Official instructions specify that the medication should be taken with a meal and water to help ensure proper absorption and manage potential side effects. No specific instructions regarding the impact of high-fat meals on the drug's effectiveness are provided.


Q: Is Venasmin suitable for people with a history of kidney stones?

Official summaries advise that caution is necessary for patients with severe kidney disease. This is related to concerns that the metabolism and clearance of the medicine may be affected in individuals with impaired kidney function.


Q: Is it described in official sources that Venasmin affects liver function?

Official documents advise caution for patients with severe liver disease. This is related to concerns that the clearance and processing of the medicine may be affected in individuals with impaired liver function.


Q: Are there any known interactions between Venasmin and herbal supplements like ginkgo?

The active substance may interact with certain herbal supplements, particularly those known for properties that may affect blood clotting. Examples of such supplements noted in various summaries include ginkgo, ginseng, garlic, and turmeric.

How should Venasmin be stored and disposed of?

The storage and disposal of Venasmin (Diosmin oral solid) must strictly adhere to the conditions documented in official regulatory labeling to ensure product stability and safety.

Storage Requirements

  • Temperature: Venasmin must be stored below 30 C.
  • Protection: It is mandatory to protect the medicine from both light and moisture.
  • Packaging: The product must be kept in its original container and the container must remain tightly closed.
  • Child Safety: The medicine is required to be stored out of the sight and reach of children.

Disposal Instructions

Official labeling directs that unused or expired Venasmin must not be thrown away via wastewater or household trash. Disposal must occur according to local pharmaceutical waste requirements to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venasmin found in:

A-Z Index: